Medicare Part D Coverage For Obesity Drugs Urged By House Appropriations Panel
Executive Summary
In the report accompanying FY 2023 HHS appropriations legislation, the House committee also addresses biosimilar uptake in Part D, Medicare dispensing fees for oral COVID-19 drugs and NIH grants for expanded access to investigational ALS drugs.
You may also be interested in...
Can Medicare Cover Obesity Drugs Without Congressional Action? Industry Builds Its Case
Obesity drug ≠ weight-loss drug, a new Pfizer-funded white paper argues in laying out a legal case for Part D coverage of obesity medicines even without legislation. Advocates hope forthcoming updates to a 2007 FDA guidance on weight management drugs will bolster the case for coverage.
Lilly’s Tirzepatide For Obesity Faces Uphill Road To Medicare Part D Acceptance
Eli Lilly’s drug could join Novo Nordisk’s Wegovy on the market in the next year or so as treatments offering significantly more weight loss than previous drugs have been able to. Could that open the door to greater access?
Paxlovid, Molnupiravir Access Threatened By ‘Dismal' Pharmacy Dispensing Fees, CMS Told
Pharmacy organization urges the Centers for Medicare and Medicaid Services to recommend a dispensing fee commensurate with the effort involved in filling scripts for the drugs.